In conclusion, we showed that HSPD1 elimination interferes with NSCLC metabolic activity causing a strong OXPHOS-dependent energetic impairment, which the cancer cells fail to overcome, highlighting HSPD1 as a powerful theranostic marker for improving lung cancer therapy. Here, HSPD1 is linked to lung carcinoma.